Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
NCT01594957 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53
Last updated 2020-12-19
Summary
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of hepatic impairment to healthy subjects.
Conditions
- Hepatic Impairment
Interventions
- DRUG
-
LCQ908
Participants will receive a single oral dose of LCQ908
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2013-04-30
- Completion
- 2013-04-30
Countries
- United States
Study Locations
More Related Trials
-
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
NCT05553470 ·Status: COMPLETED ·Phase: PHASE1
-
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
NCT00968591 ·Status: COMPLETED ·Phase: PHASE1
-
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants
NCT05490030 ·Status: WITHDRAWN ·Phase: PHASE1
-
Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment
NCT04993157 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
NCT03681457 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects
NCT01456663 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT01631097 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
NCT05610657 ·Status: COMPLETED ·Phase: PHASE1
-
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
NCT02474537 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
NCT00828932 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
NCT04887064 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT04482270 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
NCT02388620 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers
NCT01529294 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
NCT01516047 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
NCT01767688 ·Status: COMPLETED ·Phase: PHASE1
-
A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838
NCT01356550 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
NCT06576765 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
NCT04056468 ·Status: COMPLETED ·Phase: PHASE1
-
Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)
NCT01043887 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
NCT04604496 ·Status: COMPLETED ·Phase: PHASE1